The FDA approved AstraZeneca and Daiichi Sankyo's fam-trastuzumab deruxtecan in combination with pertuzumab for first-line treatment because the Destiny-Breast09 trial showed a median progression-free survival period of 40.7 months, which is superior to the standard THP regimen of 26.9 months; pertuzumab is sold by Roche.

The FDA approved AstraZeneca and Daiichi Sankyo's fam-trastuzumab deruxtecan in combination with pertuzumab for first-line treatment because the Destiny-Breast09 trial showed a median progression-free survival period of 40.7 months, which is superior to the standard THP regimen of 26.9 months; pertuzumab is sold by Roche.